Terms: = Thyroid cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Prognosis
5 results:
1. ezh2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
[TBL] [Abstract] [Full Text] [Related]
2. A clinically useful and biologically informative genomic classifier for papillary thyroid cancer.
Craig S; Stretch C; Farshidfar F; Sheka D; Alabi N; Siddiqui A; Kopciuk K; Park YJ; Khalil M; Khan F; Harvey A; Bathe OF
Front Endocrinol (Lausanne); 2023; 14():1220617. PubMed ID: 37772080
[TBL] [Abstract] [Full Text] [Related]
3. Validation of ezh2 Inhibitor Efficiency in Anaplastic thyroid Carcinoma Cell Lines.
Nakayama H; Saito N; Kasajima R; Suganuma N; Rino Y; Masudo K; Yamazaki H; Toda S; Sekihara K; Iwasaki H; Hoshino D
Anticancer Res; 2023 Mar; 43(3):1073-1077. PubMed ID: 36854530
[TBL] [Abstract] [Full Text] [Related]
4. Serous BMP8A has Clinical Significance in the Ultrasonic Diagnosis of thyroid cancer and Promotes thyroid cancer Cell Progression.
Liu K; Gao M; Qin D; Wang H; Lu Q
Endocr Metab Immune Disord Drug Targets; 2020; 20(4):591-598. PubMed ID: 31656161
[TBL] [Abstract] [Full Text] [Related]
5. LncRNA LINC00673 inhibits p53 expression by interacting with ezh2 and DNMT1 in papillary thyroid carcinoma.
Meng XF; Zhao LY; Chu XF
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2075-2083. PubMed ID: 30915752
[TBL] [Abstract] [Full Text] [Related]
